company background image
DICE

DICE Therapeutics NasdaqGM:DICE Stock Report

Last Price

US$31.79

Market Cap

US$1.5b

7D

-0.06%

1Y

81.8%

Updated

02 Feb, 2023

Data

Company Financials +

DICE Therapeutics, Inc.

NasdaqGM:DICE Stock Report

Mkt Cap: US$1.5b

DICE Stock Overview

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas.

DICE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

DICE Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DICE Therapeutics
Historical stock prices
Current Share PriceUS$31.79
52 Week HighUS$45.99
52 Week LowUS$12.64
Beta0
1 Month Change1.47%
3 Month Change-5.05%
1 Year Change81.76%
3 Year Changen/a
5 Year Changen/a
Change since IPO-13.82%

Recent News & Updates

DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

Oct 11

Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

Sep 11
Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

DICE Therapeutics GAAP EPS of -$0.58

Aug 11

Recent updates

DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

Oct 11

Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

Sep 11
Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

DICE Therapeutics GAAP EPS of -$0.58

Aug 11

DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs

Jul 18

Shareholder Returns

DICEUS PharmaceuticalsUS Market
7D-0.06%-1.0%1.7%
1Y81.8%4.6%-9.1%

Return vs Industry: DICE exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: DICE exceeded the US Market which returned -12.5% over the past year.

Price Volatility

Is DICE's price volatile compared to industry and market?
DICE volatility
DICE Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement6.8%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: DICE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: DICE's weekly volatility has decreased from 13% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201365J. Judicehttps://www.dicemolecules.com

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company’s lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications.

DICE Therapeutics, Inc. Fundamentals Summary

How do DICE Therapeutics's earnings and revenue compare to its market cap?
DICE fundamental statistics
Market CapUS$1.52b
Earnings (TTM)-US$76.86m
Revenue (TTM)n/a

0.0x

P/S Ratio

-19.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DICE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$33.88m
Gross Profit-US$33.88m
Other ExpensesUS$42.98m
Earnings-US$76.86m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.61
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did DICE perform over the long term?

See historical performance and comparison